{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:12:28Z","timestamp":1788901948181,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009021","name":"Heart Research Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014165","name":"PHARMAC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.hlc.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:29:59Z","timestamp":1783308599000},"page":"1193-1202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023\u20132025"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4476-6051","authenticated-orcid":false,"given":"Jonathan L.","family":"Ciofani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Puranik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-7372","authenticated-orcid":false,"given":"Avedis","family":"Ekmejian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usaid K.","family":"Allahwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5073-338X","authenticated-orcid":false,"given":"Shreyans","family":"Sinhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"James-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-0232","authenticated-orcid":false,"given":"Salvatore","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayanna","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinay","family":"Bhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.hlc.2026.06.001_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hlc.2026.06.001_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.hlc.2026.06.001_bib5","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hlc.2026.06.001_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hlc.2026.06.001_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hlc.2026.06.001_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hlc.2026.06.001_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.121.054539","article-title":"Summoning STRENGTH to question the placebo in REDUCE-IT","volume":"144","author":"Bostrom","year":"2021","journal-title":"Circulation"},{"issue":"10253","key":"10.1016\/j.hlc.2026.06.001_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hlc.2026.06.001_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.hlc.2026.06.001_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.033767","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy: rationale for clinically guided dose titration to optimize individual response","volume":"13","author":"Owens","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.hlc.2026.06.001_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.hlc.2026.06.001_bib14","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hlc.2026.06.001_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"issue":"23","key":"10.1016\/j.hlc.2026.06.001_bib16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.hlc.2026.06.001_bib17","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hlc.2026.06.001_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.hlc.2026.06.001_bib19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.hlc.2026.06.001_bib20","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hlc.2026.06.001_bib21","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.06.001_bib22","series-title":"Pharmaceutical Benefits Scheme Expenditure and Prescriptions Report: 1 July 2023 to 30 June 2024","year":"2025"},{"key":"10.1016\/j.hlc.2026.06.001_bib24","author":"Stats"},{"issue":"4","key":"10.1016\/j.hlc.2026.06.001_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf112","article-title":"Coronary heart disease and stroke mortality trends in Australia and New Zealand: comparison of official national mortality data and Global Burden of Disease estimates","volume":"54","author":"Zhang","year":"2025","journal-title":"Int J Epidemiol"},{"issue":"24","key":"10.1016\/j.hlc.2026.06.001_bib26","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hlc.2026.06.001_bib27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hlc.2026.06.001_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.hlc.2026.06.001_bib29","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.06.001_bib30","article-title":"Cardiovascular drug development: role of Mendelian randomization","volume":"28","author":"Ciofani","year":"2026","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.hlc.2026.06.001_bib31","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/CIRCULATIONAHA.123.066982","article-title":"The future of clinical trials","volume":"149","author":"Zannad","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.hlc.2026.06.001_bib32","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.hlc.2025.10.005","article-title":"The pursuit of truth: revisiting causation versus association in contemporary cardiovascular research","volume":"34","author":"Ciofani","year":"2025","journal-title":"Heart Lung Circ"},{"issue":"3","key":"10.1016\/j.hlc.2026.06.001_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/ehjcvp\/pvaf012","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024","volume":"11","author":"Tamargo","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"10.1016\/j.hlc.2026.06.001_bib34","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.70167","article-title":"Uptake and costs of the 60-day dispensing policy for antihypertensive medicines in Australia: a mixed methods study","volume":"224","author":"Wang","year":"2026","journal-title":"Med J Aust"},{"issue":"6","key":"10.1016\/j.hlc.2026.06.001_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950626004063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950626004063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:48:29Z","timestamp":1788900509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950626004063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1443950626004063"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2026.06.001","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023\u20132025","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}